Restoring RCAN1 dosage mitigates sleep and EEG abnormalities in a Down syndrome model

This study examined whether elevated RCAN1 protein levels contribute to sleep disruption in Down syndrome using a mouse model (Dp16). Researchers found that correcting RCAN1 dosage to normal levels partially rescued age-related sleep deficits and abnormal EEG patterns in affected mice, suggesting RCAN1 as a potential therapeutic target for sleep problems affecting 60% of individuals with Down syndrome.